PHARMACOGENOMICS IN PERSONALIZED MEDICINE: OPTIMIZING DRUG THERAPY FOR IMPROVED CLINICAL OUTCOME

Pharmacogenomics (PGx) is an emerging discipline that integrates genomic information into clinical decision-making to optimize drug therapy, enhance efficacy, and reduce adverse drug reactions. Variability in drug response among individuals is influenced by genetic polymorphisms in drug-metabolizing enzymes, transporters, and receptors.[1] Recent developments, including clinical guidelines from the Clinical Pharmacogenetics Implementation Consortium (CPIC) and regulatory support from agencies such as the FDA, have accelerated the implementation of pharmacogenomic testing in routine healthcare.[2] Applications of PGx are particularly significant in oncology, cardiology, psychiatry, and rare diseases, where genotype-guided therapy has demonstrated improved therapeutic outcomes and reduced toxicity.[3] Emerging technologies such as next-generation sequencing, artificial intelligence, and multi-omics approaches are expected to further enhance the clinical utility of pharmacogenomics. Differences in drug response among patients often arise due to genetic polymorphisms affecting drug metabolism, transport, and targets. These variations can lead to therapeutic inefficacy or adverse drug reactions (ADRs), posing significant clinical challenges.[4] The integration of pharmacogenomics into personalized medicine enables clinicians to tailor treatments, improving efficacy and minimizing toxicity.[5]